Vitiligo

Vitiligo

Vitiligo is a disease of subtraction. Melanocytes are progressively destroyed, and what remains is well-demarcated depigmented skin against normally pigmented surroundings. It affects 0.5 to 2 percent of the global population, and its visual sharpness, rather than any physical symptom, is what makes it consequential: the patches are painless. One ingredient carries an evidence grade against it here, vitamin D at Grade D on 4 studies and 300 participants, which is the thinnest graded position on this site.

Two mechanisms operate together. Oxidative stress raises hydrogen peroxide concentrations in affected epidermis to levels that impair melanocyte function, and cytotoxic T cells then target the stressed melanocytes directly. That combination explains features that are otherwise puzzling. The Koebner phenomenon, in which new patches appear at sites of trauma, follows from local stress recruiting an already-primed immune response. Premature graying of hair reflects the same loss in follicular melanocytes, and loss of colour in oral mucosa extends the process beyond skin.

The autoimmune framing is supported by company rather than by any single finding. Vitiligo clusters with thyroid disease and type 1 diabetes, and large clinical series describe that comorbidity pattern along with the age and distribution characteristics of the condition ^[1]. In children the presentation and associations differ enough to be described separately ^[2].

Vitamin D is the only graded entry, and the reason it appears at all is a repeated observational association rather than a trial result. Serum vitamin D levels have been examined specifically in vitiligo populations and reported as lower than in controls ^[3], and the receptor is expressed on both melanocytes and keratinocytes, with documented roles in melanogenesis and in dampening T-cell activity ^[4]. A Grade D rating on 4 studies is the correct weight for that: an association consistent with several possible causal directions, including reduced sun exposure among people managing a visible pigmentary condition. Related case-control work has examined vitamin D alongside markers of depression in vitiligo and alopecia areata populations, which points at the psychosocial dimension rather than at the pigment itself ^[5].

That psychosocial dimension is not incidental to the condition. Vitiligo is disfiguring in the specific sense that matters clinically, visible and unpredictable, and the measured burden falls on quality of life rather than on physical function. It is also worth stating plainly that repigmentation in vitiligo requires melanocyte repopulation from follicular reservoirs, a process that established phototherapy and immunomodulatory approaches are designed around and that no nutritional intervention has been shown to drive.

With a single Grade D ingredient across 4 studies, the honest summary of this page is that the supplement evidence for vitiligo is preliminary. Anyone with spreading depigmentation, particularly with a personal or family history of autoimmune disease, is better served by dermatologic assessment and thyroid screening than by supplementation.